Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Childhood Asthma Worsened By Stress And Depression, UB Researchers Show
Young people with asthma have nearly twice the incidence of depression compared to their peers without asthma, and studies have shown that depression is associated with increased asthma symptoms and, in some cases, death.

Regulations Seek To Crack Down On Medical ID Theft
New regulations seek to crack down on a little known form of identity theft -- medical identity theft, according to Kaiser Health News. "Armed with as little as a stolen name, Social Security number and date of birth, an imposter can walk into a doctor"s office or hospital and receive services billed to the victim or the insurance provider. Although few statistics are available, the Federal Trade Commission reports that medical identity theft accounts for 1.3 percent to 3 percent of all identity theft crime -- about 250,000 cases each year."
News of the day
Budget Solution Must Protect Health Care For Children
Dr. Dev GnanaDev, president of the California Medical Association, issued the following statement after Gov. Arnold Schwarzenegger called on the state Legislature to swiftly enact his proposed budget cuts.
Sexual Health

Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida. The study results further underpin the broad predictive and prognostic power of Agendia"s breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia"s new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions: Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract #512 Time: 5:00PM - 5:15PM Location: Level 2, West Hall D1 The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, L. J. Van "t Veer Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract # LBA515 Time: 3:00PM - 6:00PM Location: Level 2, West Hall D1 Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van "t Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators Date: Saturday, May 30, 2009 POSTER PRESENTATION Abstract #6570 Time: 2:00PM - 6:00PM Location: Level 2, West Hall C Cost effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early stage breast cancer (ESBC) patients K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #535 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guideline F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van "t Veer Date: Sunday, May 31, 2009 POSTER PRESENTATION Abstract #4036 Time: 8:00 AM - 12:00 PM Location: Level 2, West Hall C Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van "t Veer, R. Tollenaar Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #518 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Early determination of metastatic potential in breast cancer: the 70-gene signature in small tumors M. Knauer, S. Mook, V. Retç¨l, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van "t Veer, S. C. Linn Date: Monday, June 01, 2009 POSTER PRESENTATION Abstract #11083 Time: 1:00PM - 5:00PM Location: Level 2, West Hall C Combining multi-gene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas About MammaPrint(R) MammaPrint is the first "in vitro diagnostic multivariate index assay" (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests. All MammaPrint tests are conducted in Agendia"s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009